Abstract:Objective: To investigate the value of using 18F-FDG PET/CT in combination with serum lactate dehydrogenase (LDH) for prognostic evaluation of newly diagnosed small cell lung cancer (SCLC).Methods: We reviewed 118 patients with pathologically proven SCLC who underwent 18F-FDG PET/CT imaging evaluation in our hospital. Among these patients, 64 patients had extensive disease (ED) and 54 patients had limited disease (LD). The maximum standardized uptake value (SUVmax) of primary tumor was measured. A Cox proportional hazards model was used to evaluate age, sex, performance status, serum LDH, tumor stage and SUVmax on the prediction of overall survival (OS) and median survival time (MST) of patients. Subgroup analysis was performed based on the SUVmax in combination with serum LDH.Results: According to the Receiver Operating Characteristic (ROC) curve, the optimal cut-off value of SUVmax was 10.95. The AUC was 0.535 (95% CI: 0.407–0.663). The patients were divided into four groups according to the SUVmax (higher or lower than 10.95) and LDH (higher or lower than 245 U/L). The univariate and multivariate analyses showed that curative thoracic radiotherapy, Prophylactic Cranial Irradiation (PCI) and the combination of primary tumor SUVmax ≤ 10.95 and LDH ≤ 245 U/L were prognostic factors of OS in patients with all patients (p < 0.05). Smoking status, PCI, the combination of primary tumor SUVmax ≤ 10.95 and LDH ≤ 245 U/L were prognostic factors of OS in patients with LD (p < 0.05). N stage and PCI were significant predictors in both of univariate and multivariate analysis of OS for ED SCLC (p < 0.05). Among all patients, 27 had low SUVmax and normal LDH, and their MST was 36 months (95% CI: 12.98–59.02). Ninety-one patients had high SUVmax and/or high LDH, and their MST was 20 months (95% CI: 15.47–24.53). The difference between these two groups was significant (p = 0.045). In patients with LD, 16 patients had low SUVmax and normal LDH, and their MST was 72 months (95% CI: 26.00–118.0). Thirty-eight patients had high SUVmax and/or high LDH, and their MST was 27 months (95% CI: 20.80–33.21). The difference between these two groups was significant (p = 0.012). In patients with ED SCLC, 10 patients had low SUVmax and normal LDH, with an MST of 18 months (95% CI: 13.69–22.32. Fifty-four patients had high SUVmax and/or high LDH, and their MST was 12 months (95% CI: 10.61–13.39). The difference of MST between these two groups was not statistically significant (p = 0.686).Conclusion:18F-FDG PET/CT in combination with serum LDH were prognostic factors of overall survival in patients with SCLC. The prognosis of patients with LD SCLC who had low SUVmax of primary tumor and normal LDH was better than those with high SUVmax and/or high LDH.

Pretreatment Metabolic Parameters Measured By F-18-Fdg-Pet To Predict The Outcome Of First-Line Chemotherapy In Extensive-Stage Small-Cell Lung Cancer

18F-FDG PET/CT for the Early Prediction of the Response Rate and Survival of Patients with Recurrent or Metastatic Breast Cancer.

18 F-FDG PET/CT for Evaluation of Metastases in Nonsmall Cell Lung Cancer on the Efficacy of Immunotherapy.

Value of 18F-FDG PET/CT with Volume Metabolic Parameters for Prognosis Evaluation in Limited-Disease Small Cell Lung Cancer

Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer.

Quantitative F-18-FDG PET Analysis in Survival Rate Prediction of Patients with Non-Small Cell Lung Cancer

Predictive Value of Metabolic Parameters Derived from Preoperative 18F-FDG Positron Emission Tomography/computed Tomography for Brain Metastases in Patients with Surgically Resected Non-Small Cell Lung Cancer.

Predictive value of F-18-FDG PET/CT for evaluating the response to hypofractionated radiotherapy combined with PD-1 blockade in non-small cell lung cancer

Predictive value of 18F-FDG PET/CT for evaluating the response to hypofractionated radiotherapy combined with PD-1 blockade in non-small cell lung cancer

The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer

Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer

Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung Cancer

Measurement of Tumor Volume by PET to Evaluate Prognosis in Patients with Advanced Non-Small Cell Lung Cancer Treated by Non-Surgical Therapy

The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy.

Baseline and interim 18F-FDG PET/CT metabolic parameters predict the efficacy and survival in patients with diffuse large B-cell lymphoma

Prognostic Significance of Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography/computed Tomography (PET/CT) in Patients with Primary T Cell Lymphomas

The Prognostic Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Analyses of Metabolic Response Rates in Newly Diagnosed Diffuse Large B Cell Lymphoma Patients

Combining 18F‐FDG PET/CT and Serum Lactate Dehydrogenase for Prognostic Evaluation of Small Cell Lung Cancer

Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer.

Prognostic Value Of F-18-Fdg Pet/Ct In Surgical Non-Small Cell Lung Cancer: A Meta-Analysis

Prognostic Value of 2-[18F]fluoro-2-deoxy-d-glucose Uptake As Measured by PET Scan in Patients with Non-Small Cell Lung Cancer.